Effects of Semaglutide on Cognitive Function and Anxiety in Mice with Alzheimer's Disease
Author Information
Author(s): Boboc Ianis Kevyn Stefan, Dumitrelea Petrica-Daniel, Meca Andreea Daniela, Mititelu-Tartau Liliana, Bogdan Maria
Primary Institution: University of Medicine and Pharmacy of Craiova, Romania
Hypothesis
This study investigates the effects of semaglutide on cognitive function and anxiety-like behavior in a murine model of Alzheimer's disease.
Conclusion
Semaglutide may improve glycemic control and cognitive function in mice with Alzheimer's disease.
Supporting Evidence
- Semaglutide significantly reduced blood glucose levels in AD mice.
- Cognitive assessments indicated an improvement in the investigation index for SEM-treated mice.
- SEM did not significantly enhance motor and exploratory activities.
- SEM displayed a potential anxiolytic effect in the AD group.
Takeaway
Researchers gave a medicine called semaglutide to mice with Alzheimer's disease to see if it could help their thinking and reduce anxiety. It seemed to help with blood sugar and thinking skills.
Methodology
20 mice were divided into four groups and treated with either semaglutide or saline for four weeks, with various behavioral tests conducted to assess cognitive and anxiety-related outcomes.
Potential Biases
Randomization was used to assign mice to treatment groups, reducing bias risks.
Limitations
The study is a pilot investigation with a small sample size and short duration, which may limit the generalizability of the findings.
Participant Demographics
Mice included 10 wild-type and 10 transgenic mice with Alzheimer's pathology.
Statistical Information
P-Value
p = 0.0020
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website